Kaoru Mogushi

Kaoru Mogushi

Auto-generated profile, based on publicly available information

Kaoru Mogushi

Department of Systems Biology, Graduate School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Nature Communications
Verified
Journal Article
Closed access
PDF file
TYToshifumi Yae
Toshifumi Yae
KTKenji Tsuchihashi
Kenji Tsuchihashi
TITakatsugu Ishimoto
Takatsugu Ishimoto
TMTakeshi Motohara
Takeshi Motohara
MYMomoko Yoshikawa
Momoko Yoshikawa
ONOsamu Nagano
Osamu Nagano

1 March 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
MFManabu Funayama
Manabu Funayama
KOKenji Ohe
Kenji Ohe
TATaku Amo
Taku Amo
NFNorihiko Furuya
Norihiko Furuya
JYJunji Yamaguchi
Junji Yamaguchi
NHNobutaka Hattori
Nobutaka Hattori

14 April 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
STShunsuke Tsukamoto
Shunsuke Tsukamoto
TIToshiaki Ishikawa
Toshiaki Ishikawa
SISatoru Iida
Satoru Iida
MIMegumi Ishiguro
Megumi Ishiguro
KMKaoru Mogushi
Kaoru Mogushi
KSKenichi Sugihara
Kenichi Sugihara
Purpose: This study aimed to identify a novel biomarker or a target of treatment for colorectal cancer (CRC). Experimental Design: The expression profiles of cancer cells in 104 patients with CRC were examined using laser microdissection and oligonucleotide microarray analysis. Overexpression in CRC cells, especially in patients with distant metastases, was a prerequisite to select candidate genes. The mRNA expression of candidate genes was investigated by quantitative reverse transcriptase PCR (RT-PCR) in 77 patients as a validation study. We analyzed the protein expression and localization of the candidate gene by immunohistochemical study and investigated the relationship between protein expression and clinicopathologic features in 274 CRC patients. Results: Using microarray analysis, we identified 6 candidate genes related to distant metastases in CRC patients. Among these genes, osteoprotegerin (OPG) is known to be associated with aggressiveness in several cancers through inhibition of apoptosis via neutralization of the function of TNF-related apoptosis-inducing ligand. The mRNA expression of OPG in cancer tissues was significantly higher in patients with distant metastases than those without metastases. Overexpression of OPG protein was associated with significantly worse overall survival and relapse-free survival. Moreover, overexpression of the OPG protein was an independent risk factor for CRC recurrence. Conclusion: Overexpression of OPG may be a predictive biomarker of CRC recurrence and a target for treatment of this disease. Clin Cancer Res; 17(8); 2444–50. ©2011 AACR.

14 March 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YTYoko Tabe
Yoko Tabe
SYShinichi Yamamoto
Shinichi Yamamoto
KSKaori Saitoh
Kaori Saitoh
KSKazumasa Sekihara
Kazumasa Sekihara
NMNorikazu Monma
Norikazu Monma
MAMichael Andreeff
Michael Andreeff
Leukemia cells in the bone marrow must meet the biochemical demands of increased cell proliferation and also survive by continually adapting to fluctuations in nutrient and oxygen availability. Thus, targeting metabolic abnormalities in leukemia cells located in the bone marrow is a novel therapeutic approach. In this study, we investigated the metabolic role of bone marrow adipocytes in supporting the growth of leukemic blasts. Prevention of nutrient starvation–induced apoptosis of leukemic cells by bone marrow adipocytes, as well as the metabolic and molecular mechanisms involved in this process, was investigated using various analytic techniques. In acute monocytic leukemia (AMoL) cells, the prevention of spontaneous apoptosis by bone marrow adipocytes was associated with an increase in fatty acid β-oxidation (FAO) along with the upregulation of PPARγ, FABP4, CD36, and BCL2 genes. In AMoL cells, bone marrow adipocyte coculture increased adiponectin receptor gene expression and its downstream target stress response kinase AMPK, p38 MAPK with autophagy activation, and upregulated antiapoptotic chaperone HSPs. Inhibition of FAO disrupted metabolic homeostasis, increased reactive oxygen species production, and induced the integrated stress response mediator ATF4 and apoptosis in AMoL cells cocultured with bone marrow adipocytes. Our results suggest that bone marrow adipocytes support AMoL cell survival by regulating their metabolic energy balance and that the disruption of FAO in bone marrow adipocytes may be an alternative, novel therapeutic strategy for AMoL therapy. Cancer Res; 77(6); 1453–64. ©2017 AACR.

16 February 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TMTakatoshi Matsuyama
Takatoshi Matsuyama
TIToshiaki Ishikawa
Toshiaki Ishikawa
KMKaoru Mogushi
Kaoru Mogushi
TYTsuyoshi Yoshida
Tsuyoshi Yoshida
SISatoru Iida
Satoru Iida
KSKenichi Sugihara
Kenichi Sugihara
Distant metastasis is the major cause of death in colorectal cancer (CRC) patients. To identify genes influencing the prognosis of patients with CRC, we compared gene expression in primary tumors with and without distant metastasis using an oligonucleotide microarray. We also examined the expression of the candidate gene in 100 CRC patients by quantitative real‐time reverse transcription PCR and studied the relationship between its expression and the prognosis of patients with CRC. As a result, we identified MUC12 as a candidate gene involved in metastasis processes by microarray analysis. Quantitative real‐time reverse transcription PCR showed that MUC12 expression was significantly lower in cancer tissues than in adjacent normal tissues (p < 0.001). In Stages II and III CRC, patients with low expression showed worse disease‐free survival (p = 0.020). Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in Stages II and III CRC (relative risk, 8.236; 95% confidence interval, 1.702–39.849 p = 0.009). Our study revealed the prognostic value of MUC12 expression in CRC patients. Moreover, our result suggests MUC12 expression is a possible candidate gene for assessing postoperative adjuvant therapy for CRC patients.

24 August 2011 in Gut
Verified
Journal Article
Closed access
PDF file
SSShu Shimada
Shu Shimada
AMAyako Mimata
Ayako Mimata
MSMasaki Sekine
Masaki Sekine
KMKaoru Mogushi
Kaoru Mogushi
YAYoshimitsu Akiyama
Yoshimitsu Akiyama
YYYasuhito Yuasa
Yasuhito Yuasa
Background Gastric cancer is the second most frequent cause of death from cancer in the world, diffuse-type gastric cancer (DGC) exhibiting a poor prognosis. Germline mutations of CDH1, encoding E-cadherin, have been reported in hereditary DGC, and genetic and/or epigenetic alterations of CDH1 are frequently detected in sporadic DGC. Genetic alterations of TP53 are also frequently found in DGC. To examine the synergistic effect of the loss of E-cadherin and p53 on gastric carcinogenesis, a mouse line was established in which E-cadherin and p53 are specifically inactivated in the stomach parietal cell lineage. Methods Atp4b-Cre mice were crossed with Cdh1loxP/loxP and Trp53loxP/loxP mice, and the gastric phenotype of Atp4b-Cre+;Cdh1loxP/loxP;Trp53loxP/loxP double conditional knockout (DCKO) mice was examined. Results Non-polarised E-cadherin-negative parietal cells and proton pump-negative atypical foci were observed in DCKO mice. Intramucosal cancers and invasive cancers composed of poorly differentiated carcinoma cells and signet ring cells, histologically very similar to those in humans, were found from 6 to 9 months, respectively. Fatal DGC developed at 100% penetrance within a year, frequently metastasised to lymph nodes, and had tumourigenic activity in immunodeficient mice. Gene expression profiles of DGC in DCKO mice also resembled those of human DGC, and mesenchymal markers and epithelial-mesenchymal transition-related genes were highly expressed in mouse DGC as in human DGC. Conclusion This mouse line is the first genetically engineered mouse model of DGC and is very useful for clarifying the mechanism underlying gastric carcinogenesis, and provides a new approach to the treatment and prevention of DGC.